Research programme: antibacterials - NewBiotics

Drug Profile

Research programme: antibacterials - NewBiotics

Alternative Names: Lamectacin; NB 2001; NB 2030; NB 3179; NB 3180; NB 3322; NB-2179

Latest Information Update: 10 Jun 2005

Price : $50

At a glance

  • Originator NewBiotics
  • Class
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Nosocomial infections

Most Recent Events

  • 10 Jun 2005 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 10 Jun 2005 Discontinued - Preclinical for Nosocomial infections in USA (unspecified route)
  • 26 Jul 2004 NewBiotics has been acquired by Celmed BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top